Sustained immune tolerance induction in enzyme replacement therapy–treated CRIM-negative patients with infantile Pompe diseaseZoheb B. Kazi, Priya S. Kishnani, Omar Abdul‐Rahman et al.|JCI Insight|2017Cited by 72
An immune tolerance approach using transient low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe diseaseZoheb B. Kazi, Priya S. Kishnani, Ankit K. Desai et al.|Genetics in Medicine|2018Cited by 34
Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective studySi Houn Hahn, Priya S. Kishnani, David Kronn et al.|Genetics in Medicine|2018Cited by 31
Triheptanoin for the treatment of long‐chain fatty acid oxidation disorders: Final results of an open‐label, long‐term extension studyJerry Vockley, Antonio Nino Ramirez, Barbara K. Burton et al.|Journal of Inherited Metabolic Disease|2023Cited by 21
Clinical characteristics and genotypes in the ADVANCE baseline data set, a comprehensive cohort of US children and adolescents with Pompe diseasePriya S. Kishnani, Si Houn Hahn, James B. Gibson et al.|Genetics in Medicine|2019Cited by 16